Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 92

Results For "Ram"

2935 News Found

Rise of Bio-based Chemicals: Hype or Game-Changer?: Dr. Sangeeta Srivastava, Executive Director, Godavari Biorefineries
Opinion | July 28, 2025

Rise of Bio-based Chemicals: Hype or Game-Changer?: Dr. Sangeeta Srivastava, Executive Director, Godavari Biorefineries

The latest BioE3 policy builds the framework for high-performance biomanufacturing to propel the development and production


Laurus Labs allotted 531.77 acres of land by the Govt. of Andhra Pradesh
News | July 28, 2025

Laurus Labs allotted 531.77 acres of land by the Govt. of Andhra Pradesh

The company has projected Rs. 5,630 crores of investment and to provide employment to 6,350 people in three phases over a period of eight years


10.18 Cr women screened for cervical cancer under Govt. schemes
Policy | July 28, 2025

10.18 Cr women screened for cervical cancer under Govt. schemes

This achievement is part of the population-based initiative for screening, prevention, and management of Non-Communicable Diseases


GSK forges $12 billion alliance with Hengrui Pharma
News | July 28, 2025

GSK forges $12 billion alliance with Hengrui Pharma

GSK and Hengrui Pharma enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology


Jagsonpal Pharmaceuticals Q1 FY26 revenue up 23.1%
News | July 27, 2025

Jagsonpal Pharmaceuticals Q1 FY26 revenue up 23.1%

Net profit doubled to Rs. 10.8 crore, with PAT margin expanding by 560 bps to 14.3%, reflecting strong operational execution


Pfizer completes licensing agreement with 3SBio to expand oncology portfolio
News | July 24, 2025

Pfizer completes licensing agreement with 3SBio to expand oncology portfolio

3SBio will receive a payment of $1.25 billion. Pfizer will also make a $100 million equity investment in 3SBio


Lonza reports 19% growth in sales in H1
News | July 23, 2025

Lonza reports 19% growth in sales in H1

Upgrades 2025 full-year CDMO sales and margin outlook


Syngene reports Q1 FY26 revenue higher at Rs. 875 Cr
News | July 23, 2025

Syngene reports Q1 FY26 revenue higher at Rs. 875 Cr

Reported EBITDA up by 19% year-on-year with reported EBITDA margin at 25%


Roche updates on sBLA for Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma
Clinical Trials | July 21, 2025

Roche updates on sBLA for Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma

Based on the CRL, the STARGLO data do not provide sufficient evidence to support the proposed second-line DLBCL indication in the US patient population